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Oklectires . The purpose of this study was to ieter"nhte the
occurrence of sudden cardiac death or mud-stage heart fa l :sre, two
phases of the natural history of bypertrophic cardiomyopathy, In
closely related relatives .
Background. Hypertrphlc curdia nyopatlty is a genetically
transmitted cardiac disease with a particularly diverse clinical and
morphologic spectrum. Premature death usually occurs either
suddenly or as a result of progressive congestive heart failure .
Methods . We describe seven families with genetically transmit-
ted hypertrophic cardiomyopathy that were studied with echocar-
diography or necropsy, or both, and were selected because they
were known to include relatives who had incurred either prema-
ture sudden cardiac death or the end-stage phase of the disease .
Results. The seven families comprised 128 relatives; 26 died
Hypertrophic cardiomyopathy is a primary cardiac disease
that is usually genetically transmitted as an autosomal
dominant trait (1-4) . Recently, mutations in the beta-cardiac
myosin heavy chain gene have been identified in members of
families with hypertrophic cardiomyopathy (5-7), as respon-
sible for the disease .
The natural history of hypertrophic cardiomyopathy is
characteristically variable and includes patients who remain
clinically stable and relatively symptom free for long periods
of time (8-13), as well as those who experience premature
death that is sudden (1,2,14-20) or due to progressive
end-stage heart failure characterized by left ventricular
cavity enlargement, wall thinning or decreased ejection
fraction, or any combination of these abnormalities (21-28) .
However, the occurrence of such strikingly diverse clinical
profiles in closely related patients with hypertrophic cardio-
myopathy has not been fully appreciated . This study exam-
ines such distinctive clinical variability in several selected
families known to have genetically transmitted hypertrophic
cardiomyopathy .
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suddenly, and 9 developed end-stage heart failure (including 2
with head transplantation) associated with left ventricular cavity
enlargement, wall thinning or decreased contractility, alone or In
combination, as well as loss of outflow obstruction . Patients who
died suddenly (lid so at younger ages (23 ±: 10 years) than did
patients who died or required heart transplantation in the end-
stage phase of bypertrophle cardiomyopathy (42 t 8 years, p <
0.001) .
Conclusions . This study demonstrates that family members
with hypertrophic cardlomyopathy, despite a common genetic
substrate, may exhibit markedly diverse and distinct expressions
of the natural history of their disease, which occur at widely
separated periods of life.
(J Am Coil Cardiol 1993,22 .489-97)
Methods
Selection of pedigrees. The pedigrees of seven index
cases with hypertrophic cardiomyopathy, evaluated at the
National Heart, Lung, and Blood Institute, were selected for
the present study on the basis of the following criteria :
1) hypertrophic cardiomyopathy was documented in rela-
tives in two or more generations ; 2) at least one relative had
died suddenly and prematurely (i .e ., before age 40 years) of
hypertrophic cardiomyopathy ; and 3) at least one relative
was documented to have had the end-stage phase of the
disease (21-28) .
Definitions. Hyp~rtrophic cardiomyopathy
was defined
at, the demonstration by echocardiography or angiography or
at necropsy of an asymmetrically hypertrophied, nondilated
left ventricle in the absence of another cardiovascular or
systemic disease that could itself produce left ventricular
hypertrophy (29) . Family members who died suddenly and
unexpectedly before age 40 years (but in whom these mor-
phologic features could not be documented definitively be-
cause of incomplete echocardiographic, angiographiC or
necropsy data) were also judged to have died of hypertrophic
cardiomyopathy .
End-stage hypertrophic cardlomyopathy was defined as
that phase representing an evolution from the typical asym-
metrically hypertrophied and nondilated left ventricle (with
normal or increased systolic function) (29) to a disease state
characterized by left ventricular wall thinning, cavity en-
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Figure 1. Flow diagram showing clinical outcome in the 128 rela-
tives studied in the seven families with hypertrophic cardiomyopa-
thy (HCM). *Includes lb patients in whom the diagnosis of hyper
trophic cardiomyopathy was documented by echocardiography,
angiography or necropsy and also 10 other relatives without defin-
itive anatomic documentation who died suddenly and unexpectedly
before age 40 years and were assumed to have had hypertrophic
cardiomy apathy for the purpose of this study . tIncludes asymptom-
atic as well as symptomatic patients with hypertrophic cardiomyop-
athy but without evidence of the end-stage phase . MVR = mitral
valve replacement .
largement or impaired systolic function (i .e., ejection frac-
tion s45%) (30), or any combination of these abnormalities,
and associated with clinical evidence of progressive conges-
tive heart failure in the absence of hemodynamically signif-
icant coronary artery disease. In each study patient with the
end-stage phase, these morphologic and functional abnor-
malities were documented by serial observations with echo-
cardiography or contrast or radionuclide angiography or at
necropsy. Specifically, of the nine relatives identified as
having the end-stage phase, four patients fulfilled all three
diagnostic criteria (left ventricular wall thinning, cavity
enlargement and decreased ejection fraction) ; three of these
four patients also showed a decrease in the basal outflow
gradient. Two other patients in the end-stage phase had
cavity enlargement and impaired systolic function without
wall thinning, and the remaining three patients had impaired
systolic function .
! chocardkgraphy. Echocardiograms were obtained with
commercially available instruments using 2 .25- or 3 .0-MHz
transducers. Two-dimensional echocardiographic images
were obtained in several cross-sectional planes by using
standard transducer positions (31). M-mode echocardio-
grams were derived from two-dimensional images under
direct anatomic visualization . The magnitude and distribu-
tion of let ventricular hypertrophy were assessed as previ-
ously described (32) . Other cardiac dimensions were mea-
sured according to the recommendations of the American
Society of Echocardiography (33).
Assessment of bemodynandc state. The magnitude of left
ventricular outflow obstruction under basal conditions was
I.
II.
I .
II .
S01. s a s.a a ES. 4/
(22) 1171 (19) (28)
S.D. 1
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Figure 2. Pedigrees C . (top panel) and St . (bottom panel), in which
family members experienced sudden cardiac death and the end-
stage phase of hypertrophic cardiomyopathy . Black symbol = death
due to hypertrophic cardiomyopathy ; black and-white symbols =
alive but affected with hypertrophic cardiomyopathy; gray symbols =
no evidence of hypertrophic cardiomyopathy by echocardiography ;
white symbols = subject not evaluated by echocardiography ; cir.
den = female relatives; squares = male relatives; arrow = propos-
itus; t = death due to noncardiac causes o) • apparently cardiac in
origin, but insufficient data available to judge whether hypertrophic
cardiomyopathy was present . Patient Pops iu -,ors are shown in
parentheses. Roman numerals indicate generations ; arabic numerals
indicate relatives within a generation . E-S = end-stage hypertrophic
cardiomyopathy ; S .D. = sudden death due to hypertrophic cardio-
myopathy.
assessed at cardiac catheterization (17 patients) or was
estimated from the M-mode echocardiogram on the basis of
the magnitude and duration of systolic anterior motion of the
mitral valve (3 patients) (34). In those patients without
cardiac catheterization or echocardiography, the absence of
a left ventricular outflow tract plaque at necropsy was
considered to be evidence that basal outflow tract obstruc-
tion was not present (35). Outflow obstruction was cqnsid-
ered to be present if the measured or estimated subaortic
gradient was >30 mm Hg .
Statistical methods. Data are expressed as mean value ±
SD. DJid'erences between group means were assessed using
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lure 3. Pedigrees K
. (top panel} and S . (bottom ,ravel) . Because of
practical considerations with regard to the substantial size of this
family, the entire pedigree K . is not depicted here
; the excluded
portion includes four relatives who died suddenly
. *ln pedigree K .,
this patient died I day after mitral valve replacement
. Abbreviations
and symbols as in Figure a 2
.
Figure 5. Pedigree E. Patients 11.1. and 11.2
.
with hypertrophic cardiomyopathy underwent
ventricular septal ntyotomy-myectomy, 9 and 2
years, respectively, before death. Abbreviations
and symbols as in Figure 2
.
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I.
11.
Figure 4
. Pedigrees B . (top panel) and R . (bottom panel). In pedigree
B., patients 11 .1 . and 11 .2
. underwent heart transplantation because
of severe heart failure due to end-stage hypertrophic cardiomyopa-
thy
. Abbreviations and symbols as in Figure 2 .
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the unpaired Student t test; differences between proportions
were analyzed by the chi-square or Fisher exact test, as
appropriate.
Results
Analysis of pedigrees: pooled data. The seven study ped-
igrees comprise a total of 128 family members (Fig . 1). Of
these 128 relatives, 62 are currently alive, and 66 have died .
Of the 62 survivors, 26 have been documented to have
hypertrophic cardiomyopathy, and 24 are known to be free
of the disease ; in the remaining 12 relatives, the available
data were insufficient to determine whether hypertrophic
cardiomyopathy was present .
Of the 26 surviving affected relatives, 4 are in the end-
stage phase of hypertrophic cardiomyopathy, including 2
who ultimately underwent heart transplantation (at age 46
and 52 years, respectively) . Of the 66 nonsurviving relatives,
32 died of hypertrophic cardiomyopathy . Of these 32 per-
sons, 26 had sudden death (including 16 whose death was
documented by echocardiography, angiogmphy or necropsy
and 10 without anatomic documentation who died before age
40 years). Five other relatives died of end-stage heart failure,
whereas the remaining patient died after mitral valve re-
placement performed to relieve outflow obstruction and
symptoms. In summary, among the seven study pedigrees,
26 relatives with hypertrophic cardiomyopathy died sud-
denly, and 9 evolved to the end-stage phase (5 are dead, and
4 are alive).
Individual pedigree analyses of (Fig . 2 to 5) . Pedigree C .
(Fig. 2). Four of five offspring of the index case (111 .2 ., 3 ., 4 .
and 5.) died suddenly of hypertrophic cardiomyopathy at
ages 4 to 16 years; none had experienced cardiac symptoms
before death. Only one of the offspring (111 .1 .) has survived,
a 28-year old affected woman, who remains virtually asymp-
tomatic . The mother (11.3 .) is also known to have hypertro-
phic cardiomyopathy . She first experienced mild exertional
symptoms of angina and dyspnea at age 35 years ; however,
at age 55 years (10 years after her fourth child had died
suddenly), she developed symptomatic deterioration associ-
ated with left ventricular wall thinning and cavity enlarge-
ment (Fig. 6).
Pedigree St. (Fig. 2), The index patient (11 .4.) died at age
28 years of end-stage hypertrophic cardiomyopathy while
awaiting heart transplantation . Each of her three affected
siblings (11 .1 ., 2. and 3.) died suddenly at age 17, 19 and 22
years, respectively, as did her mother (1 .1) at age 32 years.
Pedigree• K. (Fig . 3). Seven relatives died suddenly of
hypertrophic cardiomyopathy, including the mother of the
index patient . A severely symptomatic cousin (11 .2.) of the
propositus (11.3 .) died in the end-stage phase at age 43 years
while awaiting heart transplantation ; 25 years before his
death from heart failure, this patient had also experienced a
cardiac arrest after running from which he was successfully
resuscitated (36).
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Figure 6. Two M-mode echocardiograms from the propositus of
pedigree C . in Figure 2 (11 .3 . and also Patient 9 in Table 2) . who
showed clinical and morphologic evidence of end-stage hypertro-
phic cardiomyopathy. A, Tracing obtained at age 50 years, when the
patient had only mild symptoms. The ventricular septum (VS) is
asymmetrically thickened (17 mm) with respect to the posterior free
wall (PW) ; the left ventricle is nondilated (48 mm in end-diastole)
and percent fractional shortening is normal (33%). B, Tracing
obtained at age 58 years when the patient had moderately severe
symptoms. The ventricular septum has thinned considerably (t4
10 mm); the left ventricle is now dilated (59 mm in end-diastole) and
percent fractional shortening is markedly decreased (19%) .
Pedigree S. (Fig . 3) . The index patient (11 .1 .) died at age
37 years in the end-stage phase of the disease ; five other
relatives died suddenly between ages 11 and 32 years (1.4 ., 5 .
and 6 .;11.2. and 111.1 .), including the mother, brother and
daughter of the index patient .
Pedigree B. (Fig. 4). Three siblings (11 .1 ., 2. and 3.)
developed end-stage heart failure ; two of these (11 .1 . and 2.)
had marked replacement scarring and ventricular enlarge-
ment (Fig, 7) and underwent heart transplantation at age 46
and 52 years, respectively, because of severe congestive
symptoms unresponsive to medical treatment ; the third
(11 .3.) is now 49 years of age and severely symptomatic . An
asymptomatic affected daughter of one of the siblings with
end-stage heart failure (111 .2.) died suddenly at age 18 years
JACC Vol. 22 . No . 2
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with a markedly hypertrophied, nondilated left ventricle
(Fig. 8).
Pedigree R. (Fig . 4) . The mother of the index patient
(1 .2 .) died at age 50 years of heart failure after developing
evidence of the end-stage phase. Of her three sons, one
(11 .1 .) died suddenly at age 16 years, whereas the other two
(11 .2. and 11 .3.) are alive with only mild symptoms .
Pedigree E. (Fig. 5) . The index patient (11 .2 .) and three
siblings (11 .4., 6. and 11 .) died suddenly of hypertrophic
cardiomyopathy at ages 18 to 40 years . The index patient
underwent ventricular septal myotomy-myectomy 2 years
before death for alleviation of outflow obstruction and
symptoms. A cousin of this patient (11 .1 .) also underwent
myotomy-myectomy but later developed the end-stage
phase and died at age 36 years .
Clinical and morphologic comparisons. Age and gender .
The 26 patients who died suddenly ranged in age from 4 to 40
years (mean 23 ± 10) (Table 1) . Nine other patients who
developed the end-stage phase of hypertrophic cans omyop-
athy ranged in age (at time of death, most recent evaluation
or heart transplantation) from 28 to 58 years (Table 2) . Data
were then analyzed, excluding the two study paticiAs w ;tti
end-stage phase who have survived to date without trans-
plantation . The remaining seven patients who either died or
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Figure 7. End-stage hypertrophic cardiomyopathy in a 46-year old
man (11 .1 . from pedigree B in Fig . 4 and Patient 7 in Table 2) .
A, Transverse section of the heart obtained after heart transplanta-
tion, showing extensive scarring and thinning of the ventricular
septum (VS), which extends into the anterior and posterior free
wall . The left ventricular (LV) cavity appears enlarged . RV = right
ventricle . B, Stop-frame echocardiogram in parasternal long-axis
view (obtained 2 weeks before heart transplantation), showing
relatively mild (18 mm) wall thickening confined to the basal anterior
ventricular septum. The left atrium (LA) is enlarged (65 mm) . C and
D, Photomicrographs of left ventricular myocardium . C, Showing
several abnormal coronary arteries with markedly thickened walls
and a narrowed lumen, dispersed in an area of replacement fibrosis .
Hematoxylin-cosin x45, reduced by 20%. D, Showing bundles of
hypertrophied cardiac muscle cells arranged in a chaotic pattern,
with adjacent cells oriented in oblique and perpendicular angles to
each other . Hematoxylin-eosin x30, reduced by 20% .
underwent heart transplantation were significantly older
than those relatives who died suddenly (42 t 8 vs . 23 ± 10
years, p < 0.001). There was no significant difference with
respect to gender between these two subgroups (i .e ., 14
[54%] of 26 patients with sudden cardiac death were female,
as were 6 [67%J of 9 patients with end-stage disease) .
Ventricular septal thickness (Tables I and 2). Among the
26 family
memo,
r.r who died suddenly, ventricular septal
494 .
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thickness judged suitable for quantitative analysis was avail-
able in 10; these values ranged from 16 to 40 mm (mean 27
7). Of the nine relatives who progressed to the end-stage
phase of the disease, septa] thickness data from the initial
echocardiographic study (before the development of marked
congestive symptoms) were judged suitable for such an
analysis in six patients and the values were significantly
lower than values in the patients who died suddenly (range
16 to 25 mm, mean 19 ± 4, p = 0 .04) .
Obstruction to left ventricular oulfow . In nine of the
patients who died suddenly, basal outflow gradient was
measured at cardiac catheterization or estimated from the
M-mode echocardiogram; gradients ranged from 0 to
63 mm Hg (average 25) (Table 1) . In the nine relatives who
evolved to the end-stage phase of the disease, basal outflow
gradient at initial evaluation ranged from 0 to 80 mm Hg
(average 30); in each of the four patients with
an initial
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Figure 8. Necropsy and echocar-
diographic findings in a previously
asyn:ptomatic 18-year old woman
(111.2 . from pedigree B. in Fig. 4
and PaVeat 9 in Table 1) who died
sudden'y at home after running up a
flight of stairs. A, Gross heart spec-
imen shows the ventricular septum
(VS) to be markedly increased in
thickness, bulging into the left ven-
tricular outflow tract and left ven-
tricular cavity, which is reduced in
size. Ao = aorta ; FW = left ven-
tricular free wall ; LA - left atrium .
B, Parasternal short-axis echocar-
diographic view from the same pa-
tient, obtained 8 months before
death . Left ventricular wall thick-
ening Is substantial, with the pre-
dominant region of hypertrophy
identified in the posterior portion of
the ventricular septum (PVS),
which measures up to 40 mm in
thickness ; calibration dots are I cm
apart. AVS = anterior ventricular
septum. C, D, and E, Photomicro-
graphs of left ventricular myocar-
dium. C, Showing an abnormally
thickened intramural coronary ar-
tery with narrowed lumen . Hema-
toxylin-eosin xSO, reduced by 20% .
D, Showing disorganized architec-
ture with adjacent bundles of hy-
pertrophied cardiac muscle.- cells ar-
ranged in a disorganized fashion
with the centrally located bundle
oriented perpendicularly to the ad-
jacent groups of cells. Hematoxy-
lin-eosin x 100, reduced by 20% .
E, Showing an aea of replacement
fibrosis. Hematoxylin-cosin x50,
reduced by 20%.
outflow gradient X40 mm Hg, the gradient decreased to zero
during the end-stage phase (Table 2) .
Histologic findings. Left ventricular myocardium suffi-
cient for histologic analysis was available in 10 of the study
patients who died of hypertrophic cardiomyopathy (7 with
sudden cardiac death and 3 with death in the end-stage phase
of the disease). In each of these 10 patients, one or two
characteristic abnormal features of hypertrophic cardiomy-
opathy were identified (37,38), including disorganization of
hypertrophied cardiac muscle cells (Fig . 71) and 8D), areas
of replacement fibrosis (Fig. 7C and SE) and intramural
coronary arteries with thickened walls and apparently nar-
rowed lumen, situated near or within areas of fibrosis (Fig .
7C and SC). In the one family (pedigree B.) in which
histologic observations were available in three relatives,
findings characteristic of hypertrophic cardiomyopathy were
documented in two brothers (both of whom underwent heart
transplantation because of end-stage hypertrophic cardiomy-
opathy), as well as the offspring of one of these brothers who
died suddenly at age 18 years .
In the three patients with end-stage hypertrophic cardio-
myopathy in whom an intact gross heart specimen was
available for detailed analysis, marked transmural replace-
ment fibrosis was present in the ventricular septum and in
portions of the free wall (Fig . 7, A and C, and Patients 6 to
8 in Table 2) .
Discussion
Natural history of hypertrophie cardimopathy. Hyper-
trophic cardiomyopathy is a primary cardiac disease for
which a broad morphologic and clinical spectrum has been
documented in numerous reports (1,2,32) . Sudden and un-
expected cardiac death may occur at a wide range of ages but
occurs most commonly early in life, between age 12 and 35
years (15-20) . Alternatively, other patients with hypertro-
phic cardiomyopathy (usually about 25 to 50 years old) may
become severely symptomatic or die by virtue of developing
an altogether dissimilar clinical course characterized by
progressive heart failure and left ventricular wall thinning,
cavity enlargement or decreased systolic function, or a
combination of these abnormalities (21-24), as well as the
loss of outflow obstruction unassociated with coronary ar-
*Includes 16 of the 26 study patients with sudden cardiac death in whom documentation of hypertrophic cardiomyopathy was available, but excludes the 10
patients with sudden death before age 40 years in whom definitive documentation of hypertrophic cardiomyopathy was not available
. tHistologic features of left
ventricle consistent with hypertrophic cardiomyopathy (i .e .,
cardiac muscle cell disorganization estimated >5% of tissue sections 1371, areas of substantial matrix
connective tissue or replacement fibrosis [381 or >1 intramural coronary artery with thickened walls and narrowed lumen [381) . #Measured at cardiac
catheterization or estimated from M-mode .chocardiogram (34); §Hypertrophied nondilated left ventricle at necropsy, cardiac catbeterization or echocardiog-
raphy, consistent with hypertrophic cardiomyopathy (29), but quantitative expression of wall thickness not available
. lNot depicted in Figure 3.9Midventricular
muscular gradient
. "*Died during sleep . CMC Disorg = cardiac muscle cell disorganization ; Echo = echocardiography ; F = female ; FC = functional class (New
York Heart Association) ; IMCA = abnormal intramural coronary arteries ; LV = left ventricular; LVOT = left ventricular outflow tract; M = male ; Pt . = patient ;
Wt, = weight; + = present ; 0 = absent; - = data not available .
tery disease (39) . Such patients in this end-stage phase
represent a distinctive part of the natural history of hyper-
trophic cardiomyopathy that is distinguished from the more
typical circumstance in this disease in which congestive
heart failure is associated with a small left ventricular cavity
and intact systolic function (1,2).
Relation of clinical outcome to genetic substrate. The
present study was designed to document the principle (uti-
lizing several retrospectively selected pedigrees) that in
hypertrophic cardioiryopathy, diverse profiles of the natural
history, such as sudden cardiac death and end-stage progres-
sion of the disease, may occur even among closely related
patients who share an identical genetic substrate . These two
divergent expressions of hypertrophic cardiomyopathy
largely occurred at different periods of life . In one study
pedigree, the mother (and index patient) was virtually
asymptomatic until age 50 years, at which time she devel-
oped progressive congestive symptoms associated with left
ventricular wall thinning and cavity enlargement; in con-
trast, four of her five offspring had previously died suddenly
before age 17 years without experiencing previous cardiac
symptoms
. In a related circumstance, two patients whc
ultimately developed end-stage hypertrophic cardiomyopa-
thy during midlife had each survived an unexpected cardiac
arrest years earlier (at a time when the left ventricle was
nondilated)
; hence, occasional patients with hypertrophic
JACC Vol. 22, No. 2
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Table 1 . Clinical and Morphologic Data in Family Members With
Hypertrophic Cardiomyopathy Who Died Suddenly
Pt No .1 Age at Death
Circumstances of
Death
Maximal LV
Thickness (mm)
LV Histology i
Basal
LVOT
Gradient
Heart
	
CMC
Initials Pedigree (yr)/Gender FC Sedentary Active Echo Necropsy wt . (g) Disorg Fibrosis
IMCA (mm Hg);
I/D.C
.
0 .111 .5
41M
I +
§
75
21S.C . C .111 .4
ION
I + §
31R .S . S.111.1 II/F II +
30
15
41D.C
.
C .111 .3 13/M I
+
23 375 -
511Z .P . 5.11 .2
158A
11 + § -
30
61K .C.
C.111 .2 161F I
+
21
310
+
0 0
0
7/G.R.
R . 11.1
161M 11 + § -
8/R.W . St . 11 .2 171M I +
25 80D + -
K.B . B .111 .2 18/F I
+
40
540 +
+
+
0
IO/K.W
.
St . 11 .3 l9/M 11 + § 960 -
II/S.S . K .II 26/F I1
+
23 500 + 0 +
631
12/H
.P .
S.1 .6 32/F III
+ §
420
50
13/V.B . S.1 .4 331F III +F"
30 470
+ +
+
0
141E.W . St . I .I 321F I 16
580
+
151J .S . K .11 .1 381M 11
+
25
560
+ +
+ 0
16/C .E . E.11.2 401E lit
+ 33 -
64
496
	
HECHT ET AL .
SUDDEN DEATH AND HEART FAILURE IN CARDIOMYOPATHY
Table 2
. Clinical and Morphologic Data in Family Members With
End-Stage Hypertrophic Cardiomyopathy
cardiomyopathy may have both aborted sudden cardiac
death and end-stage progression within their lifetime .
The profiles of the pedigrees report d here raise certain
considerations with regard to the genetic nature of hypertro-
phic cardiomyopathy . At present, it is uncertain whether the
diverse clinical presentations of hypertrophic cafdiomyopa-
thy occurring in those relatives identified in the present
study have implications with respect to the primary genetic
defect and mutations in the beta-cardiac myosin heavy chain
gene (5-7); this is a retrospective clinical investigation, and
characterization of the underlying genetic abnormality in the
families studied was beyond our initial intent and study
design .
We should also emphasize that our criteria for identifica-
tion of the end-stage phase of hypertrophic cardiomyopathy
were relatively strict and confined to those patients with
available serial documentation of left ventricular wall thin-
ning, cavity enlargement or decrease in ejection fraction .
Consequently, it is possible that other members of the
families in this study who manifested congestive heart failure
could have also had the end-stage phase, although validation
of the precise changes in left ventricular function and dimen-
sions was lacking
. Therefore, it is possible that the coexist-
ence of the end-stage phase and sudden cardiac death in
pedigrees with hypertrophic cardiomyopathy may be more
common than is currently perceived .
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